Prescribing Pattern and Pharmacoeconomic Evaluation of Antihypertensive Drugs at a Tertiary Care Hospital

Prasanth CH¹, Sathish Kumar V¹, Akhila M¹, Swathi V²

¹Pharm D, Department of Pharmacy Practice, Nirmala College of Pharmacy, Mangalagiri, Guntur, AP, India; ²Assist Professor, Department of Pharmacology, Nirmala College of Pharmacy, Mangalagiri, Guntur, AP, India.

ABSTRACT

Aim and Background: The aim of this study is to evaluate anti-hypertensive drug prescription pattern and cost analysis in tertiary care hospital. Hypertension is one of the major chronic diseases resulting in high mortality and morbidity these days. Clinical pharmacists can play a role in pharmaceutical cost management by providing an outlook to the physicians for prescribing cost-effective choices of drugs when it is clinically appropriate. Despite broad dissemination of the JNC guidelines, prescribing practices have long remained discrepant with recommendations. Methodology: An observational and cross-sectional prospective. Was conducted in General Medicine department in tertiary care hospital for a period of 6 months. The study group consists of 200 patients, both males, and females diagnosed with hypertension and co-morbid conditions. Results and Discussions: Out of 200 patients, 99 males and 101 females were identified to have prescribed with antihypertensive drugs during the study period. In combination drug therapy, total 59 medications were prescribed. Telmisartan+HCL Thiazide 18 (30.5%), Losartan+Hydrochlorothiazide 12 (20.33%) and Telmisartan+Amlodipine 7 (11.86%) were the most frequently prescribed combinations drugs. Combinational therapy contributes the highest annual cost of (3248.5 ± 401.5 INR) followed by monotherapy drugs from various classes (1956.4 ± 222.65 INR). 5204.9 INR was accounted for the total antihypertensive drugs prescribed. Conclusion: The economic studies state that 70.5% of patients had received monotherapy. The study reveals that majority of patients were treated with diuretics. They can also encourage prescribers to make cost-effective choices of drugs when clinically appropriate. Key words: Hypertension, prescription pattern, cost, anti- hypertensive drugs

CONTEXT

Aims
The Aim of This Study Is To Evaluate Anti-hypertensive Drug Prescription Pattern And Cost Analysis In Tertiary Care Hospital.

INTRODUCTION

Hypertension is one of the major chronic diseases resulting in high mortality and morbidity these days. Poor control of this highly prevalent disease can lead to the development of ischemic heart disease, stroke, and chronic renal failure.[1] Several factors like socioeconomic status, social habits sedentary lifestyle, food and poor self-health maintenance can lead to the development of hypertension.[2] Epidemiological studies demonstrate that prevalence of hypertension is increasing rapidly among urban and rural populations in India.[3-6] Selection of an evidence-based therapy with safety and low cost has important economic implications. Clinical pharmacists can play a role in pharmaceutical cost management by providing an outlook to the physicians for prescribing cost-effective choices of drugs when it is clinically appropriate. Thus, by reducing the economic burden we can enhance the quality of patient care.

The Joint National Committee (JNC) 7 guidelines recommend the appropriate antihypertensive therapy based on the best available evidence. The guidelines recommend to Initiate thiazide, ACEI, ARB, or CCB, alone or in combination. However, most recent published data showed an increased use of the more expensive Calcium Channel Blockers (CCBs) and Angiotensin Converting Enzyme Inhibitors (ACEIs) despite the lack of evidence to support that they are superior to diuretics and beta blockers in reducing morbidity and mortality of cardiovascular diseases. Despite broad dissemination of the JNC guidelines, prescribing practices have long remained discrepant with recommendations. The cost of medications has always been a barrier ineffective treatment. The prescribing pattern among doctors and patient adherence to the treatment are being influenced by the increasing prevalence of hypertension and rising expenses of its treatment.[2,3,9]

Objectives
The 6-month cross-sectional study was designed to assess the prescription pattern and cost of anti-hypertensives therapy in a tertiary care hospital.

Cost of the drug was obtained from the current index of medical specialties (CIMS)/ 1mg.com

To study the prescribing pattern of anti-hypertensive drugs through a data entry format.

SETTINGS AND DESIGN

Study design
Observational and cross-sectional prospective.

Study period
Six months (July-Dec 2017).

METHODS AND MATERIALS

Study population
The study group consists of 200 patients, both males, and females diagnosed with hypertension and co-morbid conditions.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: invoice@jbclinpharm.org

Cite this article as: Prasanth CH, Sathish Kumar V, Akhila M, Swathi V. Prescribing Pattern and Pharmacoeconomic Evaluation of Antihypertensive Drugs at a Tertiary Care Hospital. J Basic Clin Pharma 2018;9:001-003.

Data collection

Ward round participation

Daily regular ward rounds were carried out in the study site.
The economic studies state that 70.5% of patients had received monotherapy. The study reveals that majority of patients were treated with diuretics. Among combination drug therapy, Telmisartan+HCL Thiazide combination was highly prescribed. Considering the pharmacoeconomics, diuretics are more economical. It is suggested that, while starting the drug therapy economic status of the patients should be kept in consideration. Strict lifestyle modifications should be recommended to all patients who are in the pre-hypertensive stage as the cardiovascular risk factors are highly seen in these individuals. Clinical pharmacists are in the position to make suggestions and interventions that can save cost by reducing economic burden and enhance the quality of patient care. They can also encourage prescribers to make cost-effective choices of drugs when clinically appropriate.[15-16]

CONCLUSION

The economic studies state that 70.5% of patients had received

## Table 5: Distributions of patients according to therapy

<table>
<thead>
<tr>
<th>S.no</th>
<th>Type of Therapy</th>
<th>Total</th>
<th>Cost/Day in INR</th>
<th>Cost/Day in INR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Monotherapy</td>
<td>204</td>
<td>5.36± 0.61</td>
<td>1956.4 ± 222.65</td>
</tr>
<tr>
<td>2</td>
<td>Combinational therapy</td>
<td>59</td>
<td>8.90± 1.10</td>
<td>3248.5 ± 401.5</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>5204.9</td>
</tr>
</tbody>
</table>

during the study period. Prior to data collection, taken the consent of the patient/bystander Patient bystander was also well informed about the study, its objective etc.

Statistical analysis used

Data analyzed also included the results of patient’s demographics [Age, Gender, etc.] And the cost per day and cost per year by using appropriate statistical stools.

RESULTS AND DISCUSSION

Angiotensin-converting enzyme inhibitors (ACEIs) contributed 2.75% of total cost (28.4 INR), Angiotensin receptor blockers (ARBs) contributed 20.52% of total cost (211.78INR), Beta blockers contributed 21.90% of total cost (226.02INR), Diuretics contributed 33.04% of total cost (340.96 INR), Alpha-adrenergic blockers (AABs) contributed 1.57% of total cost (16.2 INR), Centrally acting agents contributed only 0.29% of total cost (3.02 INR). Alpha-adrenergic blockers and centrally acting agents (CAA) were the least prescribed. Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) were the most prescribed.[13]

In combination drug therapy, total 59 medications were prescribed. Telmisartan+HCL Thiazide 18 (30.5%), Losartan+Hydrochlorothiazide 12 (20.33%) and Telmisartan+Amlodipine 7 (11.86%) were the most frequently prescribed combinations drugs. In combination drug therapy, Telmisartan+Metoprolol shows the highest mean cost per day of INR (14.06 ± 0.00) and Amlodipine+Atenolol combination shows the lowest mean cost per day of INR (3.65 ± 1.54).

There was a significant difference in mean cost per day between various drugs in monotherapy as well as combination therapy. Also determined the total costs of antihypertensive drugs prescribed as monotherapy and in combinations during the study period. Combinational therapy contributes the highest annual cost of (3248.5 ± 401.5 INR) followed by monotherapy drugs from various classes (1956.4 ± 222.65 INR). 5204.9 INR was accounted for the total antihypertensive drugs prescribed. The present study shows that most of the patients were stable with monotherapy followed by two drug combination therapies, none of the patient’s required triple-drug therapies.[14]

REFERENCES


